Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis
Sainsbury Bradley, Bloxham Jared, Pour Masoumeh Hassan, Padilla Mariela, Enciso Reyes,
소속 상세정보
( Sainsbury Bradley ) - University of Southern California Herman Ostrow School of Dentistry Master of Science Program in Orofacial Pain and Oral Medicine
( Bloxham Jared ) - University of Southern California Herman Ostrow School of Dentistry Master of Science Program in Orofacial Pain and Oral Medicine
( Pour Masoumeh Hassan ) - University of Southern California Herman Ostrow School of Dentistry Master of Science Program in Orofacial Pain and Oral Medicine
( Padilla Mariela ) - University of Southern California Herman Ostrow School of Dentistry Clinical Dentistry
( Enciso Reyes ) - University of Southern California Herman Ostrow School of Dentistry Department of Geriatrics, Special Patients and Behavioral Science
Abstract
Background: Chronic neuropathic pain (NP) presents therapeutic challenges. Interest in the use of cannabis-based medications has outpaced the knowledge of its efficacy and safety in treating NP. The objective of this review was to evaluate the effectiveness of cannabis-based medications in individuals with chronic NP.
Methods: Randomized placebo-controlled trials using tetrahydrocannabinol (THC), cannabidiol (CBD), cannabidivarin (CBDV), or synthetic cannabinoids for NP treatment were included. The MEDLINE, Cochrane Library, EMBASE, and Web of Science databases were examined. The primary outcome was the NP intensity. The risk of bias analysis was based on the Cochrane handbook.
Results: The search of databases up to 2/1/2021 yielded 379 records with 17 RCTs included (861 patients with NP). Meta-analysis showed that there was a significant reduction in pain intensity for THC/CBD by -6.624 units (P < .001), THC by -8.681 units (P < .001), and dronabinol by -6.0 units (P = .008) compared to placebo on a 0?100 scale. CBD, CBDV, and CT-3 showed no significant differences. Patients taking THC/CBD were 1.756 times more likely to achieve a 30% reduction in pain (P = .008) and 1.422 times more likely to achieve a 50% reduction (P = .37) than placebo. Patients receiving THC had a 21% higher improvement in pain intensity (P = .005) and were 1.855 times more likely to achieve a 30% reduction in pain than placebo (P < .001).
Conclusion: Although THC and THC/CBD interventions provided a significant improvement in pain intensity and were more likely to provide a 30% reduction in pain, the evidence was of moderate-to-low quality. Further research is needed for CBD, dronabinol, CT-3, and CBDV.
키워드
Cannabidiol; Cannabis; Meta-Analysis; Neuropathic Pain; Systematic Review
원문 및 링크아웃 정보
등재저널 정보